The majority of prostate cancer (Pca) patient morbidity can be attributed to bone metastatic events, which poses a significant clinical obstacle. Therefore, a better understanding of this phenomenon is imperative and might help to develop novel therapeutic strategies. Stromal cell-derived factor 1α (SDF-1α) and its receptor CXCR4 have been implicated as regulators of bone resorption and bone metastatic development, suggesting that agents able to suppress this signaling pathway may be used as pharmacological treatments. In this study we studied if two CXCR4 receptor antagonists, Plerixafor and CTE9908, may affect bone metastatic disease induced by Pca in preclinical experimental models

Gravina, G., Mancini, A., Muzi, P., Ventura, L., Biordi, L., Ricevuto, E., et al. (2015). CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models. THE PROSTATE, 75(12), 1227-46 [10.1002/pros.23007].

CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models

JANNINI, EMMANUELE ANGELO FRANCESCO;
2015-09

Abstract

The majority of prostate cancer (Pca) patient morbidity can be attributed to bone metastatic events, which poses a significant clinical obstacle. Therefore, a better understanding of this phenomenon is imperative and might help to develop novel therapeutic strategies. Stromal cell-derived factor 1α (SDF-1α) and its receptor CXCR4 have been implicated as regulators of bone resorption and bone metastatic development, suggesting that agents able to suppress this signaling pathway may be used as pharmacological treatments. In this study we studied if two CXCR4 receptor antagonists, Plerixafor and CTE9908, may affect bone metastatic disease induced by Pca in preclinical experimental models
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/13 - Endocrinologia
English
CXCR4; Plerixafor; bone metastases; prostate cancer; Animals; Antineoplastic Agents; Antiviral Agents; Blotting, Western; Bone Neoplasms; Cell Adhesion; Cell Movement; Chemokine CXCL12; Coculture Techniques; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heterocyclic Compounds; Heterografts; Humans; Immunohistochemistry; Lymph Nodes; Lymphatic Metastasis; Male; Mice; Mice, Nude; Peptides; Prostatic Neoplasms; Receptors, CXCR4; Tomography, X-Ray Computed; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A
Gravina, G., Mancini, A., Muzi, P., Ventura, L., Biordi, L., Ricevuto, E., et al. (2015). CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models. THE PROSTATE, 75(12), 1227-46 [10.1002/pros.23007].
Gravina, G; Mancini, A; Muzi, P; Ventura, L; Biordi, L; Ricevuto, E; Pompili, S; Mattei, C; Di Cesare, E; Jannini, Eaf; Festuccia, C
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Prostate TORC 2014.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 634.63 kB
Formato Adobe PDF
634.63 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/201513
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 40
social impact